NeoGraph Analytics
Life SciencesGlobal2026 – 2032

Proteomics Market Size, Share & Forecast 2026-2032

Proteomics market at $35.03B in 2026, reaching $72.93B by 2032 at 13.0% — and why the disclosed pure-play platform sector is 121x smaller than the headline.

Revenue, 2026

$35.0B

Forecast, 2032

$72.9B

CAGR, 2026-2032

13%

Report Coverage

Global

Code: proteomics-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Proteomics is the market in this corpus where the publishers agree and are collectively measuring the wrong thing. Estimates for 2025 run from BCC Research's $31.0 billion to $41.97 billion — a spread of only 1.35x, and published CAGRs cluster between 12.0% and 16.55%. We publish BCC's series, the narrowest stated scope and the only one with an explicit exclusion list: $35.03 billion in 2026 to $72.93 billion by 2032 at 13.0%, interpolated from BCC's own base and rate and checked against BCC's own 2030 figure to within 0.14%. What the agreement conceals is visible the moment the totals meet audited revenue. One publisher puts proteomics instruments alone at $8.0 billion for 2025; Thermo Fisher Scientific's entire Analytical Instruments segment, spanning chromatography, mass spectrometry, microscopy and chemical analysis across every application, was $7.55 billion in FY2025. The same publisher's $41.2 billion total is 3.75x the combined revenue of that segment and the whole of Bruker, and 92.5% of Thermo Fisher's entire company. Meanwhile the whole disclosed revenue of the next-generation proteomics platform sector — Quanterix, SomaLogic, Standard BioTools and Seer — is $340.5 million, or 0.83% of the headline. Illumina's cash price for SomaLogic, $350 million, is roughly the whole of it. The published figures are a measure of how much protein work the world does, including buffers and gels. They are not an addressable market, and nobody writing them says so.

02

Key Highlights

1

Headline

$35.03 billion in 2026 to $72.93 billion in 2032 at 13.0%, interpolated from BCC Research's own published 2025 base and rate

2

Published 2025 estimates span only 1.35x ($31.0B-$41.97B) — agreement that reflects a shared method, not a measured market

3

One publisher's proteomics instruments line, $8.0 billion for 2025, exceeds Thermo Fisher's entire $7.55 billion Analytical Instruments segment across all applications

4

That publisher's $41.2 billion total is 3.75x Thermo Fisher Analytical Instruments plus the whole of Bruker, and 92.5% of Thermo Fisher's entire $44.56 billion company revenue

5

Disclosed FY2025 revenue of the pure-play platform sector is $340.5 million — 0.83% of the headline, a factor of 121

6

Illumina paid $350 million cash for SomaLogic, roughly equal to the entire disclosed revenue of that sector

7

One publisher's consumables category, 69.4% of its total, is defined to include buffers, chromatography columns and electrophoresis gels

03

Market Overview

Market Context

Proteomics has two meanings and one market size, which is the source of nearly every error made about it. In the first meaning, proteomics is what laboratories do to proteins: run them on gels, separate them on columns, quantify them with antibodies, identify them on mass spectrometers. On that reading a $31-41 billion global figure is defensible, because it is counting a very large base of recurring laboratory supplies and services — and one publisher says so explicitly, defining its consumables category to include buffers and electrophoresis gels. In the second meaning, proteomics is a class of new high-plex platforms intended to do for proteins what sequencing did for nucleic acids. That is what the sector's venture funding, its acquisitions and its press releases are about, and it is measurable: $340.5 million of disclosed FY2025 revenue across Quanterix, SomaLogic, Standard BioTools and Seer. The two readings differ by about 100x. The supplier structure reinforces the point: the companies that actually hold the revenue — Thermo Fisher, Bruker, Danaher, Agilent — report proteomics nowhere, because for them it is an application of instruments sold into many markets. The companies that are proteomics report revenue in the tens of millions.

Published proteomics market estimates agree unusually well — $31.0 billion to $41.97 billion for 2025, a spread of only 1.35x — and that agreement is misleading rather than reassuring. All of them are counting protein-related laboratory and service spend, and one publisher defines its consumables category to include buffers, chromatography columns and electrophoresis gels. We publish the narrowest stated scope, BCC Research's: $35.03 billion in 2026 rising to $72.93 billion by 2032 at 13.0%. The finding is the gap underneath it. The entire disclosed FY2025 revenue of the next-generation proteomics platform sector — Quanterix, SomaLogic, Standard BioTools and Seer combined — is $340.5 million, which is 0.83% of a $41.2 billion published headline. A reader who treats the headline as an addressable market for a proteomics platform is out by roughly 100x.

Market Stage

Growth

Adoption Level

Ubiquitous as a method, early as a platform market

Key Trends

Affinity proteomics has consolidated into sequencing companies: Illumina agreed to buy SomaLogic for $350 million cash plus up to $75 million in milestones (announced 23 June 2025, completed 30 January 2026), and Olink already sits inside Thermo FisherThe pure-play sector is tiny relative to its publicity: Quanterix $138.9 million, SomaLogic approximately $99.7 million, Standard BioTools $85.3 million and Seer $16.6 million in FY2025 — $340.5 million in totalMass spectrometry remains the technical centre of gravity but is reported inside diversified instrument segments: Thermo Fisher's Analytical Instruments was $7.55 billion and Bruker's BSI CALID $1.21 billion in FY2025, neither with a proteomics splitInstrument demand is flat to down: Thermo Fisher's Analytical Instruments segment grew 1% reported and was flat organically in FY2025, and Bruker's whole company declined 4% organicallyPlasma proteomics for biomarker discovery is the application pulling platform adoption, which is why the acquirers are sequencing and diagnostics companies rather than instrument makersRegulatory demand is arriving from an unexpected direction: FDA's 10 April 2025 roadmap encourages new approach methodologies in investigational new drug applications, which makes proteomic safety readouts a submission-relevant rather than purely exploratory measurement
04

Market Forecast & Data

Market Growth Forecast
2026-2032 · CAGR 13%

Base Year (2026)

$35.0B

Forecast (2032)

$72.9B

CAGR (2026-2032)

13%

Market size by year, 2026-2032, in USD Billion.
YearMarket size ($ Billion)
2026Base year$35.03B
2027$39.58B
2028$44.73B
2029$50.55B
2030$57.12B
2031$64.54B
2032$72.93B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at a constant 13.0% CAGR from BCC Research's published 2025 base. How these figures are produced.
Forecast Analysis

Our 13.0% is the bottom of the published range, applied to the lowest dated full-scope base, and the resulting series reproduces BCC Research's own 2030 figure to within 0.14% — so it is faithful to its source. Whether it is a useful forecast depends entirely on which market the reader has in mind. For protein-related tools and consumables spend, 13.0% is a claim that a very broad laboratory-supply base compounds at roughly twice nominal GDP, in a period when the largest supplier's instrument segment grew 1% reported and was flat organically, and the second-largest declined 4% organically. That is a forecast about recovering research budgets and about consumables pull-through, and it is the same bet the single-cell and spatial forecasts make. For the platform sector, the published rate is close to meaningless: a 13% rate on a $340.5 million disclosed base gives $728 million by 2032, which is a different report. The two identifiable things that could break the pattern are both step changes rather than rates — population-scale plasma proteomics contracts attached to biobank cohorts, and regulatory uptake of proteomic readouts under FDA's April 2025 new approach methodologies roadmap, which encourages their inclusion in IND submissions without requiring it or qualifying any specific assay. Readers should hold the two numbers separately and never apply a published CAGR across the boundary.

05

Market Dynamics

  • Plasma and tissue biomarker discovery in drug development, which is the application that justifies high-plex platform purchases rather than incremental mass-spectrometry capacity
  • A very wide consumables base: antibodies, assay kits, protein chips, buffers, chromatography columns and electrophoresis gels are recurring purchases independent of platform cycles, and are what makes the published market large
  • Multiomics bundling by sequencing companies, with Illumina acquiring SomaLogic and Thermo Fisher holding Olink — proteomic content sold alongside genomic content to the same customer
  • FDA's April 2025 new approach methodologies roadmap, which encourages non-animal, human-relevant data including molecular safety readouts in IND submissions and gives proteomic assays a regulatory use case
  • Falling cost per protein measured as high-plex affinity panels compete with mass spectrometry on depth-per-dollar rather than on absolute coverage
06

Market Segmentation

By Type

  • Instruments and software
  • Consumables and reagents
  • Services

By End User

  • Pharmaceutical and biopharmaceutical companies
  • Academic and research institutions
  • Clinical and reference laboratories
  • Contract research organisations

By Application

  • Mass spectrometry platforms
  • Affinity and biochip platforms
  • Protein separation and electrophoresis
  • Bioinformatics and computational analysis
07

Competitive Landscape

T

Thermo Fisher Scientific Inc.

Waltham, Massachusetts, United States

The largest supplier by a wide margin, and the reason the published market sizes are hard to credit. Its entire Analytical Instruments segment was $7.55 billion in FY2025 — less than the $8.0 billion one publisher assigns to proteomics instruments alone, in a segment where proteomics is a minority application. No proteomics split is disclosed and we assign no share.

FY2025 revenue $44.56 billion, up 4% and 2% organically. Analytical Instruments $7.55 billion, up 1% and flat organically. Life Sciences Solutions $10.37 billion, up 8% and 3% organically, which contains the Olink affinity-proteomics business acquired in 2024 without a separate revenue line.

B

Bruker Corporation

Billerica, Massachusetts, United States

The principal independent mass-spectrometry competitor in proteomics through the timsTOF line, reported inside the BSI CALID segment with no proteomics split. Position characterised from segment performance only.

FY2025 revenue $3.44 billion, up 2% reported and down 4% organically. BSI CALID, which contains mass spectrometry, was $1.21 billion, up 11% — the only growing segment. BSI NANO $1.08 billion, down 2%; BioSpin $878.8 million, down 3%.

I

Illumina, Inc.

San Diego, California, United States

Entered proteomics by acquisition rather than development, and at a price that tells you how small the addressable platform market is: $350 million in cash for SomaLogic, roughly equal to the entire disclosed FY2025 revenue of the pure-play proteomics sector.

FY2025 revenue $4.34 billion, flat year-over-year. Completed the SomaLogic acquisition on 30 January 2026 for $350 million cash plus up to $75 million in near-term milestones and royalties, acquiring an aptamer-based platform, a kitted-panel consumables stream, about 250 employees and a CLIA- and CAP-certified laboratory in Boulder, Colorado. Expects the business to be non-GAAP operating profitable in 2027.

Q

Quanterix Corporation

Billerica, Massachusetts, United States

The largest independent high-sensitivity protein-detection company by disclosed revenue, at $138.9 million in FY2025 — which is 0.34% of one published $41.2 billion market, our own division of a reported figure by a published total.

FY2025 total revenue $138.9 million, up about 1% from $137.4 million. Simoa single-molecule immunoassay platforms, heavily used in neurology biomarker work. The figure includes $21.9 million of Akoya spatial product revenue from the acquisition close date; legacy product revenue fell 11%, and collaboration and licence revenue fell 66% to $1.5 million.

S

Standard BioTools Inc.

South San Francisco, California, United States

Reshaped itself out of proteomics during the period: divested SomaLogic to Illumina and now reports $85.3 million of continuing-operations revenue from microfluidics and mass cytometry, with roughly $550 million of cash for redeployment.

FY2025 continuing-operations revenue $85.3 million, reported 24 February 2026; fourth-quarter revenue $23.8 million, down 4%, with consumables down 17% to $9.0 million and instruments up 10% to $8.5 million. Over $40 million of annualised cost savings fully operationalised, targeting positive adjusted EBITDA exiting 2026.

S

Seer, Inc.

Redwood City, California, United States

The clearest illustration of the sector's economics at current scale: FY2025 revenue of $16.6 million against operating expenses of $86.5 million, on an installed base of 82 instruments.

Proteograph nanoparticle-based unbiased proteomics, used upstream of mass spectrometry. FY2025 revenue $16.6 million, up 17%, comprising $11.2 million product and $4.9 million service, at a 51% gross margin, after installing 33 instruments during the year.

N

Nautilus Biotechnology, Inc.

Seattle, Washington, United States

Pre-commercial; no meaningful product revenue to disclose. Named because the sector's published market size is routinely cited as the opportunity such companies are addressing, and the disclosed figures show that opportunity is two orders of magnitude smaller.

Single-molecule protein-analysis platform in development, aiming at broad proteome coverage without mass spectrometry.

08

Recent Developments

26
2026Illumina, Inc.

Completed the acquisition of SomaLogic from Standard BioTools on 30 January 2026 for $350 million in cash plus up to $75 million in near-term performance milestones and royalties, acquiring an aptamer-based proteomics platform and a CLIA- and CAP-certified laboratory in Boulder, Colorado.

26
2026Thermo Fisher Scientific Inc.

Reported FY2025 revenue of $44.56 billion on 29 January 2026, with the Analytical Instruments segment at $7.55 billion, up 1% and flat organically, and Life Sciences Solutions at $10.37 billion, up 8% — the segment that contains the Olink proteomics business without a separate revenue line.

26
2026Standard BioTools Inc.

Reported FY2025 continuing-operations revenue of $85.3 million on 24 February 2026, against preliminary combined-company revenue of about $185 million including SomaLogic, and disclosed roughly $550 million of cash and investments after the divestiture.

26
2026Seer, Inc.

Reported FY2025 revenue of $16.6 million on 26 February 2026, up 17%, against operating expenses of $86.5 million, having installed 33 Proteograph instruments during the year to reach an installed base of 82.

26
2026Bruker Corporation

Reported FY2025 revenue of $3.44 billion on 12 February 2026, with the BSI CALID segment containing mass spectrometry up 11% to $1.21 billion — the only growing segment in a company that declined 4% organically.

09

Regulatory Landscape

No FDA marketing pathway applies to the bulk of proteomics products, which are sold research-use-only. The exception is a clinical proteomic test, which must either obtain device authorisation or be offered as a laboratory-developed test.Clinical Laboratory Improvement Amendments (CLIA), administered by CMS, with CAP accreditation as the practical additional requirement: this is the operative regime for clinical proteomic testing, and SomaLogic's Boulder facility holds both certifications.FDA's laboratory-developed tests final rule was vacated in its entirety by U.S. District Judge Sean D. Jordan on 31 March 2025, on the ground that LDTs are not devices under the Federal Food, Drug, and Cosmetic Act and that Congress assigned oversight to CMS under CLIA. FDA did not appeal within the 60-day window.FDA's Biomarker Qualification Program, operating under section 507 of the Food and Drug Administration Safety and Innovation Act framework as extended by the 21st Century Cures Act, is the route by which a proteomic biomarker becomes usable across multiple drug development programmes without re-justification in each IND.FDA's 10 April 2025 roadmap on phasing out animal testing requirements for monoclonal antibodies and other drugs encourages new approach methodologies, including molecular and in-silico toxicity readouts, in investigational new drug applications. It encourages rather than requires their use, and it does not qualify any specific proteomic assay.EU In Vitro Diagnostic Regulation 2017/746 governs any proteomic product placed on the EU market for a diagnostic purpose, with conformity assessment obligations scaling by risk class.
10

Research Methodology

Secondary research

  • BCC Research, Proteomics: Technologies and Global Markets, report BIO034G, published May 2025 — $27.6B (2024), $31.0B (2025), $57.2B (2030), 13.0%
  • Global Market Insights, proteomics market, report GMI5391, February 2026 — $41.2B (2025), $45.7B (2026), $126.3B (2035), 12.0%; instruments $8B in 2025
  • Thermo Fisher Scientific Inc., Form 8-K Exhibit 99.1, fourth-quarter and full-year 2025 results, 29 January 2026 (SEC EDGAR, CIK 97745)
  • Bruker Corporation, fourth-quarter and full-year 2025 financial results, 12 February 2026
  • Quanterix Corporation, Form 10-K for FY2025 (SEC EDGAR, CIK 1503274)
  • Standard BioTools Inc., Form 8-K Exhibit 99.1, Q4 and FY2025 financial results, 24 February 2026 (SEC EDGAR, CIK 1162194)
  • Seer, Inc., fourth-quarter and full-year 2025 financial results, 26 February 2026
  • Illumina, Inc., announcement of the SomaLogic acquisition, 23 June 2025; completion 30 January 2026
  • IMARC Group, proteomics market — $36.3B (2023) to $126.2B (2032), 14.4%
  • Precedence Research via BioSpace — $31.55B (2023) to $110.13B (2032), 14.9%
  • Association for Molecular Pathology v. FDA, order vacating the laboratory-developed tests final rule, 31 March 2025
  • U.S. FDA roadmap on phasing out animal testing requirements for monoclonal antibodies and other drugs, 10 April 2025

Validation: The headline is one publisher's own base advanced at its own rate, labelled as interpolation: BCC Research's $31.0 billion for 2025 becomes $35.03 billion for 2026 and $72.93 billion for 2032 at 13.0%. The internal check is that the modelled 2030 point, $57.12 billion, sits 0.14% from BCC's separately published $57.2 billion for 2030. BCC was chosen because it publishes the narrowest stated scope and is the only house in the set to publish an explicit exclusion list (protein structural analysis and protein-expression products are out of scope), which makes it the most checkable, and because it carries the lowest base among dated full-scope series. Three grounding calculations were run against audited and reported FY2025 revenue. First, one publisher's proteomics instruments line of $8.0 billion for 2025 is 1.06x Thermo Fisher Scientific's entire Analytical Instruments segment revenue of $7.55 billion, a business spanning chromatography, mass spectrometry, microscopy and chemical analysis across all applications. Second, that publisher's $41.2 billion total is 3.75x the combined $10.99 billion of Thermo Fisher's Analytical Instruments segment and the whole of Bruker, and 92.5% of Thermo Fisher's entire $44.56 billion company revenue. Third, the summed disclosed FY2025 revenue of the next-generation proteomics platform sector — Quanterix $138.9 million, SomaLogic approximately $99.7 million derived as the difference between Standard BioTools' preliminary combined-company revenue of about $185 million and its $85.3 million of continuing operations, Standard BioTools continuing $85.3 million, and Seer $16.6 million — is $340.5 million, or 0.83% of the $41.2 billion headline, a factor of 121. Illumina's $350 million cash price for SomaLogic is roughly equal to that whole sum. These are scope and plausibility tests, not market estimates: they establish that the published figures measure protein-related laboratory and service spend rather than a purchasable platform market, and they do not establish the correct figure for either reading. The SomaLogic line is our own subtraction between two of one company's disclosures; Olink, Nautilus, Bruker's proteomics line and all private vendors sit outside the $340.5 million sum, so it is a floor. Regional, country and segment shares are published as empty or as plain strings because the only source offering them presents no method, and no vendor market share is published because none is disclosed.

11

Strategic Takeaways

Decide which proteomics you mean before quoting a size. Protein-related tools and consumables spend is $31-42 billion; the disclosed next-generation platform sector is $340.5 million. The gap is about 100x and no published report flags it.

Test any proteomics headline against instrument-company revenue. A $41.2 billion market implies an instruments line larger than Thermo Fisher's entire Analytical Instruments segment, which covers far more than proteomics.

Read the consumables definition. When buffers, chromatography columns and electrophoresis gels are inside it, the total is measuring laboratory activity, not a platform opportunity.

Use the acquisition prices as the reality check. Illumina paid $350 million in cash for SomaLogic — roughly the whole pure-play sector's annual revenue, and under 1% of the published market.

Expect the sector to keep consolidating into sequencing and diagnostics companies, which also means the public disclosure this analysis depends on will keep shrinking.

12

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.